GO:0060333 type II interferon-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060333 describes the signaling cascade initiated when interferon-gamma (IFN-gamma) binds its receptor on a target cell, culminating in transcriptional regulation.
• IFN-gamma is the sole member of the type II interferon family and signals through a heterodimeric receptor composed of IFNGR1 and IFNGR2.
• The canonical pathway activates JAK1 and JAK2, leading to phosphorylation of STAT1, which translocates to the nucleus to regulate interferon-stimulated genes.
• Dysregulation of type II interferon signaling is implicated in autoinflammation, cancer immunity, and vascular pathology [2,3,8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential for dissecting causal roles of pathway components.
• EDITGENE provides comprehensive CRISPR services to study GO:0060333-related genes in disease and immunity research.
Description
The type II interferon-mediated signaling pathway (GO:0060333) is a fundamental biological process that governs cellular responses to interferon-gamma (IFN-gamma), the only known type II interferon. This pathway is initiated by IFN-gamma binding to its specific cell surface receptor and culminates in the regulation of downstream cellular processes, most notably transcription. Unlike type I interferons, which are broadly antiviral, type II interferon signaling is critical for immune regulation, host defense, and tissue homeostasis. Researchers study this pathway to understand its roles in infectious diseases, autoimmunity, and cancer [2,3,8]. The pathway's complexity and crosstalk with other signaling cascades make it a rich area for functional genomics and therapeutic targeting.
type II interferon-mediated signaling pathway At A Glance
| GO ID | GO:0060333 |
|---|---|
| GO term | type II interferon-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | gamma-interferon-mediated signaling pathway; immune interferon signaling pathway; interferon-gamma-mediated signaling pathway; interferon-gamma-mediated signalling pathway; type II IFN-mediated signaling pathway |
| Major function | Signal transduction from IFN-gamma receptor to transcriptional regulation |
| Key ligands | Interferon-gamma (IFN-gamma) |
| Key receptors | IFNGR1, IFNGR2 |
| Major kinases | JAK1, JAK2 |
| Major transcription factor | STAT1 |
What Is GO:0060333?
GO:0060333, the type II interferon-mediated signaling pathway, is defined as the series of molecular signals initiated by interferon-gamma binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, such as transcription. Interferon gamma is the only member of the type II interferon family identified to date. This pathway is synonymous with gamma-interferon-mediated signaling, immune interferon signaling, and interferon-gamma-mediated signaling.
Why Is type II interferon-mediated signaling pathway Important in Cell Biology?
The type II interferon-mediated signaling pathway is central to immune surveillance, host defense against pathogens, and regulation of inflammatory responses. Its dysregulation contributes to a spectrum of human diseases, including autoinflammatory disorders, cancer immune evasion, and vascular diseases such as abdominal aortic aneurysm [2,3,8]. Understanding this pathway at the molecular level is essential for developing targeted therapies and for interpreting CRISPR screens aimed at immune modulation.
• Controls transcriptional programs for antimicrobial defense and immune cell activation.
• Plays a critical role in tumor immune surveillance and resistance to anti-PD-1 therapy.
• Implicated in autoinflammatory diseases driven by aberrant interferon signaling [4,6].
• Contributes to vascular smooth muscle cell fate transition in abdominal aortic aneurysm.
• Cross-talks with other signaling pathways such as BMP and TNF in pulmonary hypertension.
• Serves as a paradigm for JAK-STAT signal transduction research.
• Provides targets for CRISPR-based functional genomics in immunology.
• Essential for understanding host-pathogen interactions and vaccine responses.
What Happens During type II interferon-mediated signaling pathway?
IFN-gamma Binding and Receptor Activation
In simple terms: Interferon-gamma attaches to its receptor on the cell surface, like a key fitting a lock.
The pathway begins when IFN-gamma binds to the heterodimeric receptor composed of IFNGR1 and IFNGR2 subunits. This binding induces receptor dimerization and conformational changes that bring the associated Janus kinases, JAK1 and JAK2, into close proximity. JAK1 is constitutively associated with IFNGR1, while JAK2 binds IFNGR2. The ligand-induced receptor assembly is the first committed step in type II interferon signaling.
JAK Activation and STAT1 Phosphorylation
In simple terms: The kinases JAK1 and JAK2 activate each other and then tag STAT1 with phosphate groups.
Upon receptor dimerization, JAK2 phosphorylates JAK1, and both kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNGR1. These phosphotyrosine motifs serve as docking sites for STAT1, which is then phosphorylated on tyrosine 701 by the JAKs. Phosphorylated STAT1 molecules form homodimers through SH2 domain-phosphotyrosine interactions.
STAT1 Nuclear Translocation and Gene Regulation
In simple terms: Activated STAT1 moves into the nucleus and switches on interferon-stimulated genes.
Phosphorylated STAT1 homodimers, known as gamma-activated factors (GAF), translocate to the nucleus. There, they bind to gamma-activated sequence (GAS) elements in the promoters of interferon-stimulated genes (ISGs). This binding recruits transcriptional coactivators and initiates the expression of genes involved in immune regulation, antimicrobial defense, and cell growth control.
Negative Feedback and Pathway Attenuation
In simple terms: The cell has brakes to shut down the signal after it has done its job.
The type II interferon pathway is tightly regulated by negative feedback mechanisms. Suppressors of cytokine signaling (SOCS) proteins, particularly SOCS1, are induced by STAT1 and inhibit JAK activity. Protein tyrosine phosphatases such as SHP-1 also dephosphorylate JAKs and STAT1 to terminate signaling. This attenuation prevents excessive inflammation and maintains cellular homeostasis.
Crosstalk with Other Signaling Pathways
In simple terms: The interferon-gamma signal talks to other cellular communication lines.
Type II interferon signaling intersects with multiple other pathways, including type I interferon signaling, BMP signaling, and TNF signaling [1,8]. For example, in pulmonary hypertension, TNF drives aberrant BMP signaling that interacts with endothelial and mesenchymal dysregulation. Such crosstalk modulates the intensity and duration of IFN-gamma responses and can influence disease outcomes [1,8].
Key Genes Involved in GO:0060333 type II interferon-mediated signaling pathway
The following genes encode core components of the type II interferon-mediated signaling pathway, from ligand and receptor to kinases and transcription factors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNG | Encodes interferon-gamma, the sole type II interferon ligand | Knockout models to study ligand-dependent signaling |
| IFNGR1 | Alpha subunit of the IFN-gamma receptor, binds JAK1 | Mutations linked to immunodeficiency; CRISPR KO to dissect receptor function |
| IFNGR2 | Beta subunit of the IFN-gamma receptor, binds JAK2 | Essential for receptor assembly; target for point mutation studies |
| JAK1 | Janus kinase 1, phosphorylates STAT1 | Kinase-dead knock-in models to study signaling |
| JAK2 | Janus kinase 2, activates JAK1 and phosphorylates receptor | Key target for autoinflammation and cancer research |
| STAT1 | Signal transducer and activator of transcription 1, mediates gene regulation | Central node; knockout and point mutation models widely used |
| SOCS1 | Suppressor of cytokine signaling 1, negative feedback regulator | Overexpression models to study pathway attenuation |
| SOCS3 | Suppressor of cytokine signaling 3, modulates JAK activity | Knockout models to assess inflammatory responses |
| PTPN6 | Protein tyrosine phosphatase, dephosphorylates JAKs | Regulation of signaling duration; CRISPR KO studies |
| PTPN11 | Protein tyrosine phosphatase, modulates STAT1 activation | Point mutation models in autoimmunity |
| IRF1 | Interferon regulatory factor 1, downstream transcription factor | Knockout models to study ISG expression |
| IRF9 | Interferon regulatory factor 9, part of ISGF3 complex | Crosstalk with type I interferon signaling |
| GBP1 | Guanylate binding protein 1, effector of IFN-gamma | Overexpression and KO models for antimicrobial defense |
| CXCL10 | Chemokine induced by IFN-gamma, recruits immune cells | Reporter knock-in for pathway activity |
| NOS2 | Inducible nitric oxide synthase, effector molecule | Knockout models for inflammation studies |
| CIITA | Class II transactivator, regulates MHC class II | Knock-in reporter for transcriptional output |
| FCGR1 | High-affinity IgG receptor, induced by IFN-gamma | Overexpression models for immune cell activation |
How Is type II interferon-mediated signaling pathway Regulated?
The type II interferon-mediated signaling pathway is regulated at multiple levels. Negative feedback by SOCS proteins and phosphatases (SHP-1, SHP-2) attenuates JAK-STAT signaling. Post-translational modifications of STAT1, including phosphorylation and acetylation, modulate its activity. Crosstalk with other pathways, such as BMP and TNF signaling, can either enhance or suppress IFN-gamma responses depending on cellular context. Additionally, epigenetic regulation of ISG promoters influences the magnitude of transcriptional output.
type II interferon-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNGR1 | Immunodeficiency, cancer immune evasion | Knockout in cancer cell lines |
| STAT1 | Autoinflammation, cancer | Point mutation knock-in in immune cells |
| JAK2 | Myeloproliferative neoplasms, autoimmunity | Kinase-dead knock-in in hematopoietic cells |
| SOCS1 | Inflammatory diseases, cancer | Overexpression in macrophages |
| IRF1 | Cancer, infectious disease | Knockout in epithelial cells |
Cancer Immunity and Immunotherapy Resistance
Type II interferon signaling is critical for tumor immune surveillance. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy, in part through modulation of interferon responses. Defects in IFN-gamma signaling can lead to immune evasion and poor response to checkpoint inhibitors. Understanding these mechanisms is essential for developing combination therapies.
Autoinflammatory Disorders
Dysregulated type II interferon signaling contributes to autoinflammatory conditions. For example, type I interferon-mediated autoinflammation due to DNase II deficiency highlights the importance of interferon pathway regulation [4,6]. Although these studies focus on type I interferon, they underscore the broader relevance of interferon signaling in autoinflammation [4,6].
Vascular Pathology
In abdominal aortic aneurysm, a ROS-activated CD147-type I interferon signaling axis drives vascular smooth muscle cell fate transition. While this involves type I interferon, it illustrates how interferon signaling pathways intersect with vascular disease. Type II interferon signaling may similarly influence vascular remodeling.
Pulmonary Hypertension
TNF drives aberrant BMP signaling to induce endothelial and mesenchymal dysregulation in pulmonary hypertension. This crosstalk may involve interferon signaling components, highlighting the need to study pathway interactions in disease.
From type II interferon-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IFNGR1 abolish IFN-gamma signaling? | Knockout cell line (e.g., HeLa, THP-1) |
| Does a specific STAT1 mutation affect DNA binding? | Point mutation knock-in (e.g., STAT1 Y701F) |
| Can we track pathway activation in real time? | Tagged knock-in (e.g., STAT1-GFP) |
| Does overexpression of SOCS1 suppress inflammation? | Overexpression cell line (e.g., macrophages) |
| Which genes are essential for IFN-gamma response? | CRISPR library screening |
| How does crosstalk with BMP signaling affect endothelial cells? | Knockout of BMP receptors in endothelial cells |
How to Study the type II interferon-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify ISGs after IFN-gamma treatment |
| Proteomics | Protein abundance and modifications | Quantify STAT1 phosphorylation |
| Western blot | Specific protein levels and phosphorylation | Validate JAK-STAT activation |
| Immunofluorescence | Subcellular localization of STAT1 | Monitor nuclear translocation |
| Luciferase reporter | Transcriptional activity of GAS elements | Screen for pathway modulators |
| CRISPR knockout screen | Gene essentiality for pathway function | Discover novel regulators |
| Flow cytometry | Surface marker expression (e.g., MHC-II) | Assess functional immune activation |
Transcriptomic Profiling (RNA-seq)
RNA sequencing measures global changes in gene expression following IFN-gamma stimulation. It identifies interferon-stimulated genes and can reveal pathway activity in disease models.
Proteomic Analysis
Mass spectrometry-based proteomics quantifies protein abundance and post-translational modifications, such as STAT1 phosphorylation, providing a direct readout of pathway activation.
Imaging and Reporter Assays
Fluorescence microscopy with tagged STAT1 or reporter constructs (e.g., GAS-luciferase) visualizes nuclear translocation and transcriptional activity in live cells.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens identify novel regulators of the type II interferon pathway, uncovering genes that modulate IFN-gamma responses.
How CRISPR Can Be Used to Study GO:0060333 type II interferon-mediated signaling pathway
Knockout
CRISPR knockout of core pathway genes such as IFNGR1, JAK1, JAK2, or STAT1 abolishes IFN-gamma signaling, providing definitive loss-of-function models to study pathway necessity.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to dissect specific phosphorylation sites, such as STAT1 Y701F, to understand their role in signaling.
Knock-in
Knock-in of tagged versions of pathway components (e.g., STAT1-GFP) allows real-time tracking of protein localization and interactions in live cells.
Overexpression
Overexpression of negative regulators like SOCS1 or effector molecules can model gain-of-function states and assess their impact on pathway activity and disease phenotypes.
How EDITGENE Supports type II interferon-mediated signaling pathway Research
Researchers studying type II interferon-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway function or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of this pathway.
Contact EDITGENE today to design your custom CRISPR model for type II interferon-mediated signaling pathway research.
Frequently Asked Questions About type II interferon-mediated signaling pathway
What is the type II interferon-mediated signaling pathway?
It is the series of molecular signals initiated by interferon-gamma binding to its receptor, leading to regulation of downstream cellular processes such as transcription.
What genes are involved in type II interferon-mediated signaling pathway?
Key genes include IFNG, IFNGR1, IFNGR2, JAK1, JAK2, STAT1, and downstream effectors like IRF1 and GBP1.
What is the GO ID for type II interferon-mediated signaling pathway?
The GO ID is GO:0060333.
How does interferon-gamma activate STAT1?
IFN-gamma binding induces receptor dimerization, activating JAK1 and JAK2, which phosphorylate STAT1 on tyrosine 701, leading to STAT1 dimerization and nuclear translocation.
What diseases are associated with type II interferon signaling?
Dysregulation is linked to cancer immune evasion, autoinflammatory disorders, and vascular diseases such as abdominal aortic aneurysm [2,3,4,6].
What are the synonyms for type II interferon-mediated signaling pathway?
Synonyms include gamma-interferon-mediated signaling pathway, immune interferon signaling pathway, and interferon-gamma-mediated signaling pathway.
How can CRISPR be used to study type II interferon signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of gene function in the pathway.
What is the role of SOCS1 in type II interferon signaling?
SOCS1 is a negative feedback regulator that inhibits JAK activity to attenuate the pathway.
Which transcription factors are activated by type II interferon signaling?
STAT1 homodimers (GAF) are the primary transcription factors that bind GAS elements to induce interferon-stimulated genes.
What experimental models are used to study type II interferon signaling?
Common models include knockout cell lines, point mutation knock-ins, tagged knock-ins, overexpression lines, and CRISPR screens.
Conclusion
The type II interferon-mediated signaling pathway (GO:0060333) is a cornerstone of immune regulation and host defense. Its core components, from IFN-gamma and its receptor to JAK kinases and STAT1, have been extensively characterized. Dysregulation of this pathway contributes to cancer, autoinflammation, and vascular pathology, making it a critical area of research [2,3,4,6,8]. CRISPR-based models are indispensable for dissecting causal mechanisms and identifying therapeutic targets. EDITGENE offers comprehensive services to support these efforts, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling.. Nat Rev Immunol 5(5):375-86 PMID: 15864272
- 2. Baruch EN et al.. 2025. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.. Nature 646(8084):462-473 PMID: 40836096
- 3. Zhong F et al.. 2025. ROS-activated CD147-type I interferon signaling axis drives vascular smooth muscle cell fate transition and abdominal aortic aneurysm progression.. Redox Biol 86:103780 PMID: 40803247
- 4. Schnappauf O et al.. 2025. Type I interferon-mediated autoinflammation in two unrelated patients due to a proximal intronic splice site variant in DNASE2.. Res Sq PMID: 41472683
- 5. Douam F et al.. 2017. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo.. mBio 8(4) PMID: 28811340
- 6. Rodero MP et al.. 2017. Type I interferon-mediated autoinflammation due to DNase II deficiency.. Nat Commun 8(1):2176 PMID: 29259162
- 8. Garcia-Hernandez ML et al.. 2025. TNF drives aberrant BMP signaling to induce endothelial and mesenchymal dysregulation in pulmonary hypertension.. JCI Insight 10(14) PMID: 40569693
